Showing 3101-3110 of 4166 results for "".
- Samsung Bioepis Announces Analytical Similarity Data on SB11 (Ranibizumab) at ARVOhttps://modernod.com/news/samsung-bioepis-announces-analytical-similarity-data-on-sb11-ranibizumab-at-arvo/2479155/Samsung Bioepis announced results from a study analyzing structural and functional similarity between SB11, a proposed ranibizumab biosimilar, and Lucentis (ranibizumab). The study results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2021
- Stealth BioTherapeutics Announces Poster Presentation at ARVOhttps://modernod.com/news/stealth-biotherapeutics-announces-poster-presentation-at-arvo/2479132/Stealth BioTherapeutics announced that the company will have a poster presentation with a live discussion at the upcoming 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting, which is being held May 1-7, 2021. The poster showcases
- Lantronix Contributes to eSight Design, Enabling Individuals With Serious Visual Impairment to Seehttps://modernod.com/news/lantronix-contributes-to-esight-design-enabling-individuals-with-serious-visual-impairment-to-see/2479082/Lantronix announced that its engineering services team supported eSight Corp. in the development of an enhanced vision device that enables individuals with serious visual impairment to see. eSight was recently recognized as a manufacturer of the Best Wearable/Healthcare Hardware/Soft
- World Council of Optometry Passes Resolution Calling for a Standard of Care for Myopia Managementhttps://modernod.com/news/world-council-of-optometry-passes-resolution-calling-for-a-standard-of-care-for-myopia-management/2479073/The World Council of Optometry (WCO) Board of Directors unanimously approved a resolution advising optometrists to incorporate a standard of care for myopia management within their practices. “Myopia is increasing at an alarming rate, as are the risks for vision impairment associated with
- Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopiahttps://modernod.com/news/eyenovia-announces-first-patients-enrolled-in-phase-3-study-of-microline-for-presbyopia/2478667/Eyenovia announced that the first set of patients has been enrolled in the company’s phase 3 VISION-1 study of MicroLine, its proprietary pilocarpine formulation delivered via its Optejet dispenser, for the
- Janssen Acquires Rights to Hemera Biosciences Investigational Gene Therapy for Late-Stage AMDhttps://modernod.com/news/janssen-acquires-rights-to-hemera-biosciences-investigational-gene-therapy-for-late-stage-amd/2478615/Janssen Pharmaceuticals announced the acquisition of rights to Hemera Biosciences’s investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy. Financial terms of the transaction with
- Eluminex Biosciences Announces Closing of $50 Million Series A Financinghttps://modernod.com/news/eluminex-biosciences-announces-closing-of-50-million-series-a-financing/2478597/China-based Eluminex Biosciences announced the completion of a $50 million Series A Financing, which will be used to develop a pipeline addressing critical unmet medical needs in vision-threatening diseases for patients. The financing was co-led by Lilly Asia
- Ocutrx’s Oculenz Advances from AR Headset to Full Surgery Visualization Theatrehttps://modernod.com/news/ocutrxs-oculenz-advances-from-ar-headset-to-full-surgery-visualization-theatre/2477779/Ocutrx Vision Technologies, the maker of augmented-extended reality (AR/XR) glasses that provide a new surgical viewing experience for retinal surgeons and patients, said it is launching new technology that provides modern options for surgery visualization.
- Studies Yield Mixed Findings for Investigational Drug Abicipar in Wet AMDhttps://modernod.com/news/studies-yield-mixed-findings-for-investigational-drug-abicipar-in-wet-amd/2477703/The investigational drug abicipar pegol is noninferior to ranibizumab for achieving stable vision in people with wet age-related macular degeneration (AMD), according to a pair of phase-3 trials, as reported by Reuters.wet Abicipar
- Not All With AMD May Need Continuing Treatmenthttps://modernod.com/news/not-all-with-amd-may-need-continuing-treatment/2477294/A small number of patients with neovascular age-related macular degeneration (AMD) continue to maintain good vision years after cessation of anti-VEGF therapy, according to an analysis of trial results, as reported by Reuters. Howe